Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
He is also part of the following speaker's bureaus: Merck; Eli Lilly; Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a contributor to our newsletters.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
